#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

#### FORM 8-K

#### CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 26, 2013

#### Bacterin International Holdings, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-34951	20-5313323
(Commission File Number)	(IRS Employer Identification No.)
600 Cruiser Lane Belgrade, Montana	59714
(Address of Principal Executive Offices)	(Zip Code)

(406) 388-0480

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 7.01 Regulation FD Disclosure.

The Company has issued a press release entitled "Bacterin Announces Selection of Executive Search Firm" which is attached as Exhibit 99.1 and incorporated herein.

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

### Item 9.01. Financial Statements and Exhibits.

# (d) Exhibits.

Exhibit No	Description
99.1	Press Release of Bacterin International Holdings, Inc. dated April 26, 2013 entitled "Bacterin Announces Selection of Executive Search Firm"

## SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 26, 2013

BACTERIN INTERNATIONAL HOLDINGS, INC.

By: /s/ John Gandolfo Name: John Gandolfo Title: CFO and Interim Co-CEO

# EXHIBIT INDEX



# Bacterin Announces Selection of Executive Search Firm

**BELGRADE, MT, April 26, 2013** -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced the selection of O'Hara Associates, Inc. of Deerfield, Illinois to assist in the recruitment of a Chief Executive Officer.

The recommendation to retain the firm was made by the Board's Nominations and Corporate Governance Committee. "Our selection of O'Hara Associates was based on its expertise and history of locating senior executives for companies in the medical technology sector", said Jon Wickwire, Director and Chairman of Corporate Governance and Nominating Committee for Bacterin International. "While we have already received a number of candidates, our goal will be to move through the selection process prudently and expeditiously so that we can focus on growing the business and developing the markets we serve."

The Search Committee engaged in an extensive process that included the review of three proposals and numerous interviews with search consultants from around the country.

O'Hara Associates is headed by Dan O'Hara who brings more than 20 years of experience in executing retained search projects at the CEO level for various client organizations within the medical device, pharmaceutical, and Healthcare IT sectors.

#### **About Bacterin International Holdings**

Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

## About O'Hara Associates, Inc.

Headquartered in Deerfield, Illinois, our experience spans more than 20 years in retained executive search consulting. Our client base includes large and midcap multinational, public and private enterprises, as well as a range of premier private equity and venture financed companies. For more information about our firm please visit us at: <u>www.oharainc.com</u>

#### **Important Cautions Regarding Forward-looking Statements**

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's ability to advelop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's ability to advelop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forw

Contact: COCKRELL GROUP Rich Cockrell 877.889.1972 investorrelations@thecockrellgroup.com cockrellgroup.com